AALL0331: Standard risk B-precursor acute lymphoblastic leukemia (Alan Homans, MD)
AALL0232: High risk B-precursor acute lymphoblastic leukemia (Alan Homans, MD)
CALGB 50402: A phase II trial of extended induction Galiximab (anti-CD80 monoclonal antibody) plus Rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL). (Barbara Grant, MD)
CALGB 90401: A randomized double-blind placebo controlled phase III trial comparing Docetaxel and Prednisone with and without Bevacizumab in men with hormone refractory prostate cancer. (George Philips, MD)
IND/Antigenics C-100-12-Part II: A multi-center, randomized phase III study of adjuvant oncophage versus observation in patients with high risk of recurrence after surgical treatment for renal cell carcinoma (Part I CHRMS 01-297) (Mark Plante, MD)
IND/IMCLONE CP02-0452: Randomized phase III study of Docetaxel or Pemetrexed with or without Cetuximab in patients with recurrent or progressive non-small cell lung cancer after platinum-based therapy (Christian Thomas, MD)
IND/Merck/EMD 121974-009: A multicenter, open-label, randomized, uncontrolled, phase II trial in subjects with recurrent glioblastoma multiforme to investigate the clinical activity, safety, and tolerability of EMD 121974 administered as a single agent in doses of 500 mg and 2000 mg. (Susan Burdette-Radoux, MD)
OTHER/Memorial Sloan Kettering: A multi-center phase II study of BMS 247550 in indolent lymphoproliferative disorders (Barbara Grant, MD)
NSABP C-08: A phase III clinical trial comparing infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) every two weeks with Bevacizumab to the same regimen without Bevacizumab for the treatment of patients with resected stages II and III carcinoma of the colon (Julie Olin, MD)
RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, 1, or 2 breast cancer. (Deborah Rubin, MD and James Wallace III, MD)
VCC 0501: A phase II trial of Arimidex added sequentially to Zoladex in premenopausal women with metastatic breast cancer (Susan Burdette-Radoux, MD)
VCC 0503: A pilot study of the effect of IV iron in addition to Erythropoietin for the anemia of myelodysplastic syndrome (George Philips, MD)
VCC 0505: Effect of Faslodex on atypical endometrial hyperplasia (Emmanuel N. Soultanakis, MD)
For more information about these studies, call Holli McFadden, Clinical Trials Office, at 802 656-2178.